摩熵化学
数据库官网
小程序
打开微信扫一扫
首页 分子通 化学资讯 化学百科 反应查询 关于我们
请输入关键词

3-(3-羟基丙氨基)-1-丙醇 | 2158-67-0

中文名称
3-(3-羟基丙氨基)-1-丙醇
中文别名
——
英文名称
3,3'-(methylazanediyl)bis(propan-1-ol)
英文别名
3-[3-hydroxypropyl(methyl)amino]propan-1-ol
3-(3-羟基丙氨基)-1-丙醇化学式
CAS
2158-67-0
化学式
C7H17NO2
mdl
——
分子量
147.217
InChiKey
PZWOAAMXFPKLPM-UHFFFAOYSA-N
BEILSTEIN
——
EINECS
——
  • 物化性质
  • 计算性质
  • ADMET
  • 安全信息
  • SDS
  • 制备方法与用途
  • 上下游信息
  • 反应信息
  • 文献信息
  • 表征谱图
  • 同类化合物
  • 相关功能分类
  • 相关结构分类

物化性质

  • 沸点:
    164-165 °C(Press: 13 Torr)
  • 密度:
    1.005±0.06 g/cm3(Predicted)

计算性质

  • 辛醇/水分配系数(LogP):
    -0.4
  • 重原子数:
    10
  • 可旋转键数:
    6
  • 环数:
    0.0
  • sp3杂化的碳原子比例:
    1.0
  • 拓扑面积:
    43.7
  • 氢给体数:
    2
  • 氢受体数:
    3

安全信息

  • 海关编码:
    2922199090
  • 危险性防范说明:
    P264,P280,P302+P352,P337+P313,P305+P351+P338,P362+P364,P332+P313
  • 危险性描述:
    H315,H319
  • 储存条件:
    存储条件:2-8°C,干燥。

SDS

SDS:ba1ccc64f448f92aac32bc7ad852f2b5
查看

上下游信息

  • 上游原料
    中文名称 英文名称 CAS号 化学式 分子量

反应信息

  • 作为反应物:
    描述:
    3-(3-羟基丙氨基)-1-丙醇potassium carbonateN,N-二异丙基乙胺 作用下, 以 二氯甲烷N,N-二甲基甲酰胺 为溶剂, 反应 1.0h, 生成
    参考文献:
    名称:
    [EN] ACRIDIN-9-YL-AMINE, QUINOLIN-9-YL-AMINE, 1 -AMINO-9H-THIOXANTHENE-9-ONE AND BENZO[B][1,5]NAPHTHYRI DIN-10-YL-AMINE DERIVATIVES AS AUTOPHAGY INHIBITORS FOR TREATING CANCER
    [FR] DÉRIVÉS D'ACRIDIN-9-YL-AMINE, DE QUINOLIN-9-YL-AMINE, DE 1 -AMINO-9H-THIOXANTHÈNE-9-ONE ET DE BENZO[B][1,5]NAPHTYRIDIN-10-YL-AMINE UTILSÉS COMME INHIBITEURS DE L'AUTOPHAGIE POUR LE TRAITEMENT DU CANCER
    摘要:
    本公开提供了一种脱氧胸苷-9-基胺、喹啉-9-基胺、1-氨基-9H-噻吩并[1,5]苯并并[1,5]萘啉-10-基胺衍生物和结构相关化合物,用作治疗癌症的自噬抑制剂。本描述公开了示例化合物的合成和表征,以及其药理数据(例如第77页至155页;示例1至22;化合物A;化合物1至21;表1至3)。
    公开号:
    WO2021142065A1
  • 作为产物:
    描述:
    3-[(3-甲氧基-3-氧代丙基)-甲基氨基]丙酸甲酯 在 lithium aluminium tetrahydride 作用下, 以 四氢呋喃 为溶剂, 反应 1.5h, 以75%的产率得到3-(3-羟基丙氨基)-1-丙醇
    参考文献:
    名称:
    [EN] ACRIDIN-9-YL-AMINE, QUINOLIN-9-YL-AMINE, 1 -AMINO-9H-THIOXANTHENE-9-ONE AND BENZO[B][1,5]NAPHTHYRI DIN-10-YL-AMINE DERIVATIVES AS AUTOPHAGY INHIBITORS FOR TREATING CANCER
    [FR] DÉRIVÉS D'ACRIDIN-9-YL-AMINE, DE QUINOLIN-9-YL-AMINE, DE 1 -AMINO-9H-THIOXANTHÈNE-9-ONE ET DE BENZO[B][1,5]NAPHTYRIDIN-10-YL-AMINE UTILSÉS COMME INHIBITEURS DE L'AUTOPHAGIE POUR LE TRAITEMENT DU CANCER
    摘要:
    本公开提供了一种脱氧胸苷-9-基胺、喹啉-9-基胺、1-氨基-9H-噻吩并[1,5]苯并并[1,5]萘啉-10-基胺衍生物和结构相关化合物,用作治疗癌症的自噬抑制剂。本描述公开了示例化合物的合成和表征,以及其药理数据(例如第77页至155页;示例1至22;化合物A;化合物1至21;表1至3)。
    公开号:
    WO2021142065A1
点击查看最新优质反应信息

文献信息

  • METHOD FOR PRODUCING CIS- AND TRANS-ENRICHED MDACH
    申请人:BASF SE
    公开号:US20170260115A1
    公开(公告)日:2017-09-14
    A process for preparing trans-enriched MDACH, including: distilling an MDACH starting mixture in the presence of an auxiliary, which is an organic compound having a molar mass of 62 to 500 g/mol, a boiling point at least 5° C. above the boiling point of cis,cis-2,6-diamino-1-methylcyclohexane, and 2 to 4 functional groups, each of which is independently an alcohol group or a primary, secondary or tertiary amino group. The MDACH starting mixture includes 0 to 100% by weight of 2,4-MDACH and 0 to 100% by weight of 2,6-MDACH, based on the total amount of MDACH present in the MDACH starting mixture. The MDACH starting mixture includes both trans and cis isomers. Trans-enriched MDACH includes 0 to 100% by weight of 2,4-MDACH and 0 to 100% by weight of 2,6-MDACH, where the proportion of trans isomers in the mixture is higher than the proportion of trans isomers in the MDACH starting mixture.
    制备富含反式异构体MDACH的方法,包括:在辅助剂的存在下蒸馏MDACH起始混合物,所述辅助剂是一种有着62至500克/摩尔的摩尔质量、沸点至少比顺式、顺式-2,6-二氨基-1-甲基环己烷的沸点高出至少5摄氏度,并且具有2至4个官能团,每个官能团独立地是醇基团或一级、二级或三级氨基团的有机化合物。MDACH起始混合物包括以MDACH起始混合物中MDACH总量为基础的0至100%重量的2,4-MDACH和0至100%重量的2,6-MDACH。MDACH起始混合物包括反式和顺式异构体。富含反式异构体的MDACH包括以2,4-MDACH和2,6-MDACH的0至100%重量为基础,其中混合物中反式异构体的比例高于MDACH起始混合物中反式异构体的比例。
  • DIMER COMPOUNDS, AND USE IN BINDING TOXIC REPEATS OF RNA
    申请人:EXPANSION THERAPEUTICS, INC.
    公开号:US20200207744A1
    公开(公告)日:2020-07-02
    Provided herein are compounds and methods for modulating abnormal repeat expansions of gene sequences. More particularly, provided are dimeric inhibitors of RNA and the uses of such inhibitors in regulating nucleotide repeat expansions, e.g., to treat Myotonic Dystrophy Type 1 (DM1), Myotonic Dystrophy Type 2 (DM2), Fuchs dystrophy, Huntington Disease, Amyotrophic Lateral Sclerosis, or Frontotemporal Dementia.
    本文提供了一些化合物和方法,用于调节基因序列异常重复扩增。更具体地,提供了RNA二聚体抑制剂以及这些抑制剂在调节核苷酸重复扩增方面的用途,例如治疗肌萎缩性脊髓侧索硬化症1型(DM1)、肌萎缩性脊髓侧索硬化症2型(DM2)、Fuchs角膜萎缩症、亨廷顿病、肌萎缩侧索硬化症或额颞型痴呆症。
  • [EN] NANOMATERIALS<br/>[FR] NANOMATÉRIAUX
    申请人:GUIDE THERAPEUTICS INC
    公开号:WO2021141969A1
    公开(公告)日:2021-07-15
    Lipid nanoparticle compositions for delivery of nucleic acids are described. In various embodiments the lipid nanoparticle contains an ionizable lipid of the Formula (I). Methods of using such lipid nanoparticle compositions to achieve targeted delivery of therapeutic cargo without the need for a targeting ligand are also provided.
    描述了用于传递核酸的脂质纳米粒子组合物。在各种实施例中,脂质纳米粒子包含化学式(I)的可离子化脂质。还提供了使用这种脂质纳米粒子组合物实现靶向传递治疗载体而无需靶向配体的方法。
  • Sulfonamide compound
    申请人:Matsubara Koki
    公开号:US20090048223A1
    公开(公告)日:2009-02-19
    A compound represented by the formula (1) [A represents a nitrogen-containing saturated ring; m represents an integer of 0 to 2; n represents an integer of 1 to 4; G 1 represents hydrogen atom, chlorine atom, hydroxyl group, an alkoxy group, or amino group; G 2 represents a halogen atom, hydroxyl group, cyano group, carboxy group, an alkyl group, an alkenyl group, an alkynyl group, an alkoxy group, an alkylthio group, an amino group, an alkylsulfinyl group, an alkylsulfonyl group, or an aryl group; G 3 represents hydrogen atom, a halogen atom, hydroxyl group, cyano group, carboxy group, an alkyl group, an alkenyl group, an alkynyl group, an alkoxy group, an alkylthio group, an amino group, an alkoxycarbonyl group, an acyl group, an acyloxy group, an alkylsulfinyl group, an alkylsulfonyl group, or an aryl group; Y represents a single bond, or —C(R 3 )(R 4 )— (R 3 and R 4 represent hydrogen atom, or an alkyl group, or alkylene groups which combine together to form a saturated hydrocarbon ring group); G 4 represents hydroxyl group (Y is a single group), or —N(R 1 )(R 2 ) (R 1 and R 2 represent hydrogen atom, an alkyl group, an aralkyl group, an alkenyl group, an alkynyl group, a saturated heterocyclic group, an alkylsulfonyl group, an acyl group, or an amidino group); G 5 is a substituent on a ring-constituting carbon atom of A, and represents hydrogen atom, fluorine atom, or an alkyl group] or a salt thereof, or a derivative thereof that is a prodrug, which potently inhibits Rho kinase.
    由以下化学式表示的化合物:[A代表含氮饱和环;m表示0到2的整数;n表示1到4的整数;G1代表氢原子、氯原子、羟基、烷氧基或氨基;G2代表卤原子、羟基、氰基、羧基、烷基、烯基、炔基、烷氧基、烷硫基、氨基、烷氧羰基、酰基、乙酰氧基、烷基磺基、烷基磺酰基或芳基;G3代表氢原子、卤原子、羟基、氰基、羧基、烷基、烯基、炔基、烷氧基、烷硫基、氨基、烷氧羰基、酰基、乙酰氧基、烷基磺基、烷基磺酰基或芳基;Y代表单键,或-C(R3)(R4)-(R3和R4代表氢原子、烷基或烷烯基,它们结合在一起形成饱和碳氢环基);G4代表羟基(Y是单个基),或-N(R1)(R2)(R1和R2代表氢原子、烷基、芳基、烯基、炔基、饱和杂环基、烷基磺酰基、酰基或胺基);G5是A的环构成碳原子上的取代基,代表氢原子、氟原子或烷基]或其盐、或作为前药的衍生物,其强力抑制Rho激酶。
  • How Much Is Enough? Perspectives of Care Recipients and Professionals on the Sufficiency of In-Home Care
    作者:Nancy Morrow-Howell、Enola Proctor、Philip Rozario
    DOI:10.1093/geront/41.6.723
    日期:2001.12.1
    Purpose of the Study: This study sought to increase knowledge about the impact of rater role on the assessment of in-home supportive care. The authors compared the perspectives of care recipients and professionals on one aspect of the broad concept of quality of care in home care—the sufficiency of the amount of care provided by informal and formal caregivers. Design and Method: Sufficiency of home care was assessed through concurrent elderly persons' self-report through telephone interview and nurse clinical report based on in-home interviews with the elder. Care was assessed in terms of the sufficiency of the amount of informal and formal assistance received to meet functional dependency needs. Statistical analyses compared the ratings of elder and professional. Results: Professional ratings of the sufficiency of care were significantly lower than those of the elderly care recipients. From the perspective of both care recipients and professionals, sufficiency of care was significantly related to coresidence of elder and caregiver, and to caregiver health. Implications: Consistent with previous literature, rater role was found to influence the assessment of the sufficiency of in-home care. Researchers and providers should recognize that care recipient and professional ratings are not interchangeable.
    研究目的:本研究旨在增加对评估家庭支持护理中评估者角色影响的认识。作者比较了护理接受者和专业人员在家庭护理质量这一广泛概念的一个方面——非正式和正式护理人员提供的护理量的充分性上的看法。设计与方法:通过电话访谈评估老年人的自我报告和基于与老人的家访护士临床报告来评估家庭护理的充分性。护理根据满足功能依赖需求的非正式和正式帮助的充分性进行评估。统计分析比较了老年人和专业人士的评分。结果:专业人士对护理充分性的评分显著低于老年护理接受者的评分。从护理接受者和专业人员的角度来看,护理的充分性显著与老人和护理人员的共同居住情况以及护理人员的健康状况相关。启示:与以往文献一致,评估者角色被发现会影响家庭护理充分性的评估。研究人员和服务提供者应认识到护理接受者和专业评分并不可互换。
查看更多

同类化合物

(N-(2-甲基丙-2-烯-1-基)乙烷-1,2-二胺) (4-(苄氧基)-2-(哌啶-1-基)吡啶咪丁-5-基)硼酸 (11-巯基十一烷基)-,,-三甲基溴化铵 鼠立死 鹿花菌素 鲸蜡醇硫酸酯DEA盐 鲸蜡硬脂基二甲基氯化铵 鲸蜡基胺氢氟酸盐 鲸蜡基二甲胺盐酸盐 高苯丙氨醇 高箱鲀毒素 高氯酸5-(二甲氨基)-1-({(E)-[4-(二甲氨基)苯基]甲亚基}氨基)-2-甲基吡啶正离子 高氯酸2-氯-1-({(E)-[4-(二甲氨基)苯基]甲亚基}氨基)-6-甲基吡啶正离子 高氯酸2-(丙烯酰基氧基)-N,N,N-三甲基乙铵 马诺地尔 马来酸氢十八烷酯 马来酸噻吗洛尔EP杂质C 马来酸噻吗洛尔 马来酸倍他司汀 顺式环己烷-1,3-二胺盐酸盐 顺式氯化锆二乙腈 顺式吡咯烷-3,4-二醇盐酸盐 顺式双(3-甲氧基丙腈)二氯铂(II) 顺式3,4-二氟吡咯烷盐酸盐 顺式1-甲基环丙烷1,2-二腈 顺式-二氯-反式-二乙酸-氨-环己胺合铂 顺式-二抗坏血酸(外消旋-1,2-二氨基环己烷)铂(II)水合物 顺式-N,2-二甲基环己胺 顺式-4-甲氧基-环己胺盐酸盐 顺式-4-环己烯-1.2-二胺 顺式-4-氨基-2,2,2-三氟乙酸环己酯 顺式-2-甲基环己胺 顺式-2-(苯基氨基)环己醇 顺式-2-(氨基甲基)-1-苯基环丙烷羧酸盐酸盐 顺式-1,3-二氨基环戊烷 顺式-1,2-环戊烷二胺 顺式-1,2-环丁腈 顺式-1,2-双氨甲基环己烷 顺式--N,N'-二甲基-1,2-环己二胺 顺式-(R,S)-1,2-二氨基环己烷铂硫酸盐 顺式-(2-氨基-环戊基)-甲醇 顺-2-戊烯腈 顺-1,3-环己烷二胺 顺-1,3-双(氨甲基)环己烷 顺,顺-丙二腈 非那唑啉 靛酚钠盐 靛酚 霜霉威盐酸盐 霜脲氰